LYB002V14
/ Luye Group
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 13, 2023
A Phase 1 Trial of Recombinant COVID-19 Trivalent Protein Vaccine （CHO Cell）LYB002V14 in Booster Vaccination
(clinicaltrials.gov)
- P1 | N=120 | Not yet recruiting | Sponsor: Guangzhou Patronus Biotech Co., Ltd.
New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 1
Of
1
Go to page
1